NASDAQ:RDNT

RadNet Stock Forecast, Price & News

$22.11
-0.13 (-0.58 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.86
Now: $22.11
$22.22
50-Day Range
$18.35
MA: $21.84
$23.98
52-Week Range
$11.63
Now: $22.11
$25.49
Volume147,489 shs
Average Volume198,074 shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.52
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.
RadNet logo

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDNT
CUSIPN/A
Phone(310) 478-7808
Employees6,157
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.15 billion
Cash Flow$3.47 per share
Book Value$4.63 per share

Profitability

Net Income$14.76 million

Miscellaneous

Market Cap$1.16 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

Headlines

RadNet (RDNT) Upgraded to Buy: Here's Why
April 19, 2021 |  finance.yahoo.com
RadNet (NASDAQ:RDNT) Stock Price Down 4.2%
April 8, 2021 |  americanbankingnews.com
RadNet (NASDAQ:RDNT) Trading 4% Higher
March 29, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.48 out of 5 stars

Medical Sector

562nd out of 2,018 stocks

Medical Laboratories Industry

9th out of 39 stocks

Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$22.11
-0.13 (-0.58 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











RadNet (NASDAQ:RDNT) Frequently Asked Questions

Is RadNet a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RadNet stock.
View analyst ratings for RadNet
or view top-rated stocks.

What stocks does MarketBeat like better than RadNet?

Wall Street analysts have given RadNet a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but RadNet wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is RadNet's next earnings date?

RadNet is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for RadNet
.

How were RadNet's earnings last quarter?

RadNet, Inc. (NASDAQ:RDNT) announced its quarterly earnings data on Sunday, March, 7th. The medical research company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by $0.04. The medical research company had revenue of $308.50 million for the quarter, compared to the consensus estimate of $300.62 million. RadNet had a negative net margin of 0.98% and a negative trailing twelve-month return on equity of 2.72%. The company's quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.21 EPS.
View RadNet's earnings history
.

How has RadNet's stock been impacted by COVID-19 (Coronavirus)?

RadNet's stock was trading at $17.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RDNT stock has increased by 28.4% and is now trading at $22.11.
View which stocks have been most impacted by COVID-19
.

What guidance has RadNet issued on next quarter's earnings?

RadNet issued an update on its FY 2021 Pre-Market earnings guidance on Monday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.25-1.3 billion, compared to the consensus revenue estimate of $1.22 billion.

What price target have analysts set for RDNT?

2 brokers have issued 12 month price objectives for RadNet's shares. Their forecasts range from $23.00 to $26.00. On average, they expect RadNet's share price to reach $24.50 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price.
View analysts' price targets for RadNet
or view top-rated stocks among Wall Street analysts.

Who are RadNet's key executives?

RadNet's management team includes the following people:
  • Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 75, Pay $1.91M)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 50, Pay $739.18k)
  • Mr. Norman R. Hames, Pres & COO of Western Operations (Age 65, Pay $803.5k)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 60, Pay $814.56k)
  • Mr. Ranjan Jayanathan, Chief Information Officer & GM of eRAD - Radiology Information Technology Division
  • Mr. Mital Patel, Exec. VP of Financial Planning & Analysis and Chief Admin. Officer (Age 35)
  • Ms. Laura Foster BSRT, MPH, J.D., Sr. VP of Compliance & Regulatory Affairs
  • Mr. David Jeffrey Katz, Exec. VP & Gen. Counsel (Age 57)
  • Ms. Ruth Louisa Wilson, Sr. VP of HR & Director (Age 57)
  • Dr. John V. Crues III, VP, Medical Director & Director (Age 71)

What is Howard G. Berger's approval rating as RadNet's CEO?

174 employees have rated RadNet CEO Howard G. Berger on Glassdoor.com. Howard G. Berger has an approval rating of 45% among RadNet's employees. This puts Howard G. Berger in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), OPKO Health (OPK), The Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Pfizer (PFE) and AT&T (T).

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

Who are RadNet's major shareholders?

RadNet's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.16%), Dalton Greiner Hartman Maher & Co. (0.13%), State of Alaska Department of Revenue (0.06%) and Everence Capital Management Inc. (0.02%). Company insiders that own RadNet stock include B Kaplan Survivor's Tru Karen, John V Crues, Lawrence L Levitt, Mark Stolper, Michael L Md Sherman, Michael N Murdock, Norman R Hames and Ruth Louisa Villigerwilson.
View institutional ownership trends for RadNet
.

Which institutional investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., and State of Alaska Department of Revenue. Company insiders that have sold RadNet company stock in the last year include John V Crues, Lawrence L Levitt, Norman R Hames, and Ruth Louisa Villigerwilson.
View insider buying and selling activity for RadNet
or view top insider-selling stocks.

Which institutional investors are buying RadNet stock?

RDNT stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., and Everence Capital Management Inc..
View insider buying and selling activity for RadNet
or or view top insider-buying stocks.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $22.11.

How much money does RadNet make?

RadNet has a market capitalization of $1.16 billion and generates $1.15 billion in revenue each year. The medical research company earns $14.76 million in net income (profit) each year or $0.29 on an earnings per share basis.

How many employees does RadNet have?

RadNet employs 6,157 workers across the globe.

What is RadNet's official website?

The official website for RadNet is www.radnet.com.

Where are RadNet's headquarters?

RadNet is headquartered at 1510 COTNER AVE, LOS ANGELES CA, 90025.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at (310) 478-7808 or via email at [email protected]


This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.